Overview

Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is conducted to assess the relative bioavailability of MTX administered subcutaneously via a prefilled pen (50mg/mL) compared with MTX administered via IM injection (25mg/mL).
Phase:
Phase 1
Details
Lead Sponsor:
medac GmbH
Collaborator:
PPD
Treatments:
Methotrexate